Natco Pharma Ltd has obtained approval for marketing its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets in the US market.
The drug is used in the treatment of migraine headache with or without warning signs that occur prior to the onset of headache.
The Hyderabad-based company had already commenced shipments of the product which was being launched by its marketing partner, Breckenridge Pharmaceuticals.
Natco estimates the market to be around $250 million (before generic launch – as of December 31, 2012).